Rectal Tumors Clinical Trial
Official title:
Efficacy and Tolerability of a Preoperative Oral Nutritional Supplement (PreOP Booster) vs. Placebo in Surgical Patients (Pilot Study)
Verified date | May 2010 |
Source | Fresenius Kabi |
Contact | n/a |
Is FDA regulated | No |
Health authority | Netherlands: Medical Ethics Review Committee (METC) |
Study type | Interventional |
The aim of this pilot study is to investigate effectiveness, tolerability and safety of an oral nutritional supplement (PreOP Booster), given to rectal tumour patients prior to low anterior resection.
Status | Completed |
Enrollment | 20 |
Est. completion date | November 2009 |
Est. primary completion date | November 2009 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - rectal tumour with indication for elective low anterior resection (open surgery, not laparoscopic surgery) or abdominoperineal resection (APR) - preoperative radiotherapy (5x5 Gy) or chemoradiation - loop ileostoma or colostoma; Exclusion Criteria: - severe malnutrition - severe renal insufficiency - diabetes mellitus I or II - concomitant thyroid medication - corticosteroids - diuretic medication and antihypertensive medication - known or suspected allergy to any component of the investigational product(s) |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care
Country | Name | City | State |
---|---|---|---|
Netherlands | Medical Center Alkmaar | Alkmaar |
Lead Sponsor | Collaborator |
---|---|
Fresenius Kabi |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Immunoinflammatory parameters | on day -2, -1, 1, 2, 3, 5, and 7 | No | |
Primary | Antioxidant / oxidant parameters | on day -2, 1, 3, 5, and 7 | No | |
Primary | Ischemia / reperfusion injury parameters | on day -2, 1, 3, 5, and 7 | No | |
Secondary | pre-and postoperative discomfort (well-being) | on day -1, and 0 | No | |
Secondary | hand grip strength | on day -2, 1, 2, 3, 5, and 7 | No | |
Secondary | GI tolerance | on day -1, 0, 1, 2, and 7 | No | |
Secondary | Safety | on day -1, 0, 1, 2, 3, 5, and 7 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03573791 -
Biomarkers for Predicting Neoadjuvant Chemoradio-resistance for Middle-low Advanced Rectal Cancer
|
||
Completed |
NCT01912586 -
Early Intervention for Erectile Dysfunction After Laparoscopic Resection for Rectal Cancer
|
Phase 4 | |
Completed |
NCT02017509 -
Immunoscore in Rectal Cancer
|
||
Terminated |
NCT03258541 -
Organ-sparing With TraceIT® for Rectal Cancer Radiotherapy
|
N/A | |
Recruiting |
NCT03074461 -
Transverse Coloplasty vs. Side-to-end Anastomosis Following Low Anterior Resection (LAR): CSAR Trial
|
N/A | |
Completed |
NCT03871790 -
Peptide-based Immunization for Colon- and and Pancreas-carcinoma
|
||
Completed |
NCT02746224 -
Reconstruction Techniques and Vascular Approach After Laparoscopic Left Hemicolectomy and Rectum Low Anterior Resection
|
N/A |